Novocure to present tumor treating fields data at upcoming oncology congresses

BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields (TTFields) therapy at two upcoming oncology meetings in October, according to a press release statement. The announcement comes ahead of the company’s earnings report scheduled for October 30.

The company plans to showcase pre-clinical data at the European Association of Neuro-Oncology Meeting in Prague from October 16-19, highlighting TTFields therapy’s potential to enhance radiosensitivity in glioblastoma cells by downregulating DNA repair pathways. According to InvestingPro data, Novocure has maintained strong revenue growth of 14.58% over the last twelve months, despite challenging market conditions.

Additionally, at the European Society for Medical Oncology Congress in Berlin from October 17-21, Novocure will present a post-hoc analysis of its Phase 3 PANOVA-3 trial. The analysis examines the efficacy of TTFields therapy based on daily device usage and cancer antigen 19-9 levels in patients with unresectable, locally advanced pancreatic adenocarcinoma.

The PANOVA-3 trial evaluated TTFields therapy used alongside gemcitabine and nab-paclitaxel as a first-line treatment compared to chemotherapy alone.

TTFields are electric fields that exert physical forces to kill cancer cells through various mechanisms while minimally affecting healthy cells due to their different properties. The therapy is designed to work in conjunction with other cancer treatments such as chemotherapy and radiotherapy.

Novocure currently has commercialized products approved in certain countries for treating adult patients with glioblastoma, non-small cell lung cancer, and malignant pleural mesothelioma. The company continues to explore TTFields therapy’s application in additional cancer types through various clinical trials.

In other recent news, Novocure announced that its Phase 3 METIS trial showed a statistically significant delay in brain metastases progression for non-small cell lung cancer patients treated with Tumor Treating Fields (TTFields) therapy. The trial results, presented at a major oncology meeting, indicated a 28% lower risk of intracranial progression when compared to standard care alone. Additionally, Japan’s Ministry of Health approved Novocure’s Optune Lua device for use with certain inhibitors in treating advanced lung cancer, following positive results from the Phase 3 LUNAR trial. This trial demonstrated a 3.3-month improvement in median overall survival for patients using Optune Lua in combination with other treatments.

Meanwhile, Novocure has decided to terminate its LUNAR-4 trial for metastatic non-small cell lung cancer, citing the availability of real-world evidence. In Europe, Spain has approved the inclusion of TTFields therapy in its National Health System for adult patients with newly diagnosed glioblastoma, enhancing access to this treatment. H.C. Wainwright has reiterated its Buy rating for Novocure, maintaining a price target of $38.00, following the METIS trial data presentation. These developments reflect Novocure’s ongoing efforts to expand the reach and efficacy of its cancer therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.